메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

New Dimensions of Guangdong Animation and Trendy Toys Exhibition: Bridging cultures through art and imagination

GUANGZHOU, China, Oct. 14, 2025 -- News report from GDToday. On October 10, 2025, South China's Guangdong province brought its vibrant animation and trendy toy culture to Tokyo with the "New Dimensions of Guangdong Animation and Trendy Toys Exhibition" at Belle Salle Akihabara, a hub for Japanese pop culture. The event, celebrating the 2025 China-Japan-ROK Year of Cultural Exchange, attracted over 10,000 visitors, including creative industry professionals, students, and fans from both countries. Guangdong has a long legacy in animation. Masters such as T
- 김장윤(JASON KIM) 기자
- 2025-10-14 18:42
Sharjah Airport Authority partners with e& UAE to offer free SIMs to incoming visitors

SHARJAH, UAE, Oct. 14, 2025 -- The Sharjah Airport Authority (SAA) has signed a cooperation agreement with e& UAE to provide incoming tourists with a free visitor SIM card upon arrival at Sharjah Airport. The partnership aims to enhance the travel experience and strengthen digital services. The service will enable visitors to connect to the internet as soon as they arrive. Each user receives 10 GB of free data, valid for 24 hours, allowing access to essential applications such as maps, taxi bookings, digital payments, messaging, and other online services.&
- 김장윤(JASON KIM) 기자
- 2025-10-14 18:22
Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults

-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- -- Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fold for hMPV and 4 fold for PIV3 (≥10 fold increases in PIV3 PreF-specific antibodies) were observed -- -- Interim analysis from RSV re-vaccination trial demonstrates ≥60% higher trend in RSV neutralizing antibodies for Clover's RSV vaccine compared head-to-head versus AREXVY (GSK) i
- 김갑성 기자
- 2025-10-14 18:18
CNFinance Holdings Limited Regains Compliance with NYSE ADS Trading Price Requirement

GUANGZHOU, China, Oct. 14, 2025 -- CNFinance Holdings Limited (NYSE: CNF) ("CNFinance" or the "Company"), a leading home equity loan service provider in China, today announced that it has regained compliance with the New York Stock Exchange ("NYSE") continued listing standard for minimum share price under Section 802.01C of the NYSE Listed Company Manual ("Price Criteria"). As announced on April 18, 2025, CNFinance was notified by NYSE on April 7, 2025, that the Company was not in compliance with the Price Criteria, as the average closing price o
- 황정호 기자
- 2025-10-14 18:05
'NBA Cares x Sands Cares Community Impact Week' a Success

[ 메디채널 황정호 기자 ] Five days of community engagement unites over 2,200 volunteers and community members NBA stars join forces to spread compassion through basketball MACAO, Oct. 14, 2025 -- The final showdown of The NBA China Games 2025 took the court Sunday at The Venetian Arena. Alongside the games, the "NBA Cares x Sands Cares Community Impact Week" wrapped up a fun and meaningful week of community outreach events. Running Oct. 8-12, the five-day initiative built on the excitement of the major international sports event to bring together diverse local communities in
- 황정호 기자
- 2025-10-14 18:04
Infosys Chosen by NHSBSA to Deliver a New Workforce Management Solution for the NHS in England and Wales

Next-Generation solution supports the NHS 10-year Health Plan and the mission to create a workforce that is fit for the future LONDON and BENGALURU, India, Oct. 14, 2025 -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced that it has been awarded a £1.2 billion, 15-year contract by the NHS Business Services Authority (NHSBSA) to deliver the Future NHS Workforce Solution. Infosys will develop a cutting-edge, data-driven workforce management solution that will replace the current Electronic Sta
- 김갑성 기자
- 2025-10-14 18:02
$1 MILLION BERGGRUEN PHILOSOPHY PRIZE AWARDED TO MICHAEL SANDEL

World-renowned philosopher elevates public discourse and illuminates ethical and civic questions of our time LOS ANGELES, Oct. 14, 2025 -- The Berggruen Institute today named political philosopher Michael Sandel as the 2025 Laureate of the Berggruen Prize for Philosophy & Culture. One of the world's leading thinkers and public intellectuals, Sandel has profoundly impacted how we think about justice, ethics, markets, and democracy today. The $1 million award is given annually to individuals whose ideas shape human self-understanding and advancement in a rapidly changing worl
- 김장윤(JASON KIM) 기자
- 2025-10-14 18:00
Solidion Technology Will Avoid Substantially Dilutive Share Sales

Company Intends to Shun Highly Toxic Financing Structures and May Consider Long-Term or Strategic Partners For Future Capital Needs DALLAS, Oct. 14, 2025 -- Solidion Technology Inc. ("Solidion" or the "Company") (Nasdaq: STI), an advanced battery technology solutions provider, today reaffirmed its commitment to protect shareholder value by avoiding financing structures that could result in substantial dilution to existing investors. Jaymes Winters, Chief Executive Officer of Solidion Technology, stated: "Our focus remains on building intri
- 황정호 기자
- 2025-10-14 18:00
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

[ 메디채널 김갑성 기자 ] - Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG, Oct. 14, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently completed the pre-New Drug Application (NDA) consultation with China National Medical Products Administration (NMPA) for denifanstat (ASC40) for the treatment of moderate-to-severe acne
- 김갑성 기자
- 2025-10-14 18:00
$1 MILLION BERGGRUEN PHILOSOPHY PRIZE AWARDED TO MICHAEL SANDEL

World-renowned philosopher elevates public discourse and illuminates ethical and civic questions of our time LOS ANGELES, Oct. 14, 2025 -- The Berggruen Institute today named political philosopher Michael Sandel as the 2025 Laureate of the Berggruen Prize for Philosophy & Culture. One of the world's leading thinkers and public intellectuals, Sandel has profoundly impacted how we think about justice, ethics, markets, and democracy today. The $1 million award is given annually to individuals whose ideas shape human self-understanding and advancement in a rapidly changing worl
- 김장윤(JASON KIM) 기자
- 2025-10-14 18:00

이전

81 82 83 84 85 86 87 88 89 90

많이 본 기사

최근기사

2025-11-02_SUN

2025-11-01_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 02일 06시 00분